Keywords: b-ms, re-file, vanlev, nda, year-end, bristol-myers, squibb

B-MS to re-file Vanlev NDA by year-end

Article | 25 September 2001

Print This

Bristol-Myers Squibb has announced that it plans to refile its New DrugApplication in the USA for Vanlev (omapatrilat), a vasopeptidase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in